Cargando…

Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study

PURPOSE: One of the most important long-term side effects of therapy for rheumatoid arthritis (RA) is the elevation of liver function tests, with earlier studies reporting an elevation of more than 1× the upper limit of normal (>1 × ULN). The current study expands the literature by comparing the...

Descripción completa

Detalles Bibliográficos
Autores principales: Akhlaghi, Saeed, Sahebari, Maryam, Mahmoodi, Mahmoud, Yaseri, Mehdi, Mansournia, Mohammad Ali, Rafatpanah, Houshang, Zeraati, Hojjat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186305/
https://www.ncbi.nlm.nih.gov/pubmed/30349273
http://dx.doi.org/10.2147/TCRM.S172836
_version_ 1783362836169228288
author Akhlaghi, Saeed
Sahebari, Maryam
Mahmoodi, Mahmoud
Yaseri, Mehdi
Mansournia, Mohammad Ali
Rafatpanah, Houshang
Zeraati, Hojjat
author_facet Akhlaghi, Saeed
Sahebari, Maryam
Mahmoodi, Mahmoud
Yaseri, Mehdi
Mansournia, Mohammad Ali
Rafatpanah, Houshang
Zeraati, Hojjat
author_sort Akhlaghi, Saeed
collection PubMed
description PURPOSE: One of the most important long-term side effects of therapy for rheumatoid arthritis (RA) is the elevation of liver function tests, with earlier studies reporting an elevation of more than 1× the upper limit of normal (>1 × ULN). The current study expands the literature by comparing the trends of transaminase changes caused by conventional and biologic disease-modifying antirheumatic drugs (DMARDs). PATIENTS AND METHODS: The drug categories examined were methotrexate (MTX) and all other nonbiologic DMARDs. Where RA patients exhibited inadequate response to conventional DMARDs (cDMARDs), we added biologic DMARDs (bDMARDs) to the treatment. We compared the trend of changes in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the patients receiving MTX with the trend observed in the patients whose treatment encompassed both bDMARDs and MTX. The comparison was conducted using random intercept models, which are a type of linear mixed effects model. RESULTS: This work involved 512 RA patients (MTX: 450, MTX + infliximab [INF]: 26, MTX + etanercept [ETA]: 36), whose ALT and/or AST levels were measured in 1,786 visits (MTX: 1,543, MTX + INF: 107, MTX + ETA: 136). ALT and/or AST elevations greater than 1 × ULN were observed in 344 (19.3%) visits (MTX: 295 [19.1%], MTX + INF/ETA: 49 [20.2%]). In this study, the trends of ALT and AST changes increased when receiving MTX, while the INF/ETA addition decreased these trends. The random intercept models indicated that changes in the mean ALT levels were significantly different over the time for MTX and MTX + INF/ETA groups (β [SE] =−0.190 [0.093], P= 0.040) but changes in the mean AST levels were nonsignificantly different over the time for such groups (β [SE] =−0.099 [0.064], P=0.120). CONCLUSION: Despite a higher incidence of elevated transaminases during the use of MTX + INF/ETA, the combination of INF/ETA with MTX reduced transaminase levels and returned ALT levels to normal concentrations.
format Online
Article
Text
id pubmed-6186305
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61863052018-10-22 Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study Akhlaghi, Saeed Sahebari, Maryam Mahmoodi, Mahmoud Yaseri, Mehdi Mansournia, Mohammad Ali Rafatpanah, Houshang Zeraati, Hojjat Ther Clin Risk Manag Original Research PURPOSE: One of the most important long-term side effects of therapy for rheumatoid arthritis (RA) is the elevation of liver function tests, with earlier studies reporting an elevation of more than 1× the upper limit of normal (>1 × ULN). The current study expands the literature by comparing the trends of transaminase changes caused by conventional and biologic disease-modifying antirheumatic drugs (DMARDs). PATIENTS AND METHODS: The drug categories examined were methotrexate (MTX) and all other nonbiologic DMARDs. Where RA patients exhibited inadequate response to conventional DMARDs (cDMARDs), we added biologic DMARDs (bDMARDs) to the treatment. We compared the trend of changes in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the patients receiving MTX with the trend observed in the patients whose treatment encompassed both bDMARDs and MTX. The comparison was conducted using random intercept models, which are a type of linear mixed effects model. RESULTS: This work involved 512 RA patients (MTX: 450, MTX + infliximab [INF]: 26, MTX + etanercept [ETA]: 36), whose ALT and/or AST levels were measured in 1,786 visits (MTX: 1,543, MTX + INF: 107, MTX + ETA: 136). ALT and/or AST elevations greater than 1 × ULN were observed in 344 (19.3%) visits (MTX: 295 [19.1%], MTX + INF/ETA: 49 [20.2%]). In this study, the trends of ALT and AST changes increased when receiving MTX, while the INF/ETA addition decreased these trends. The random intercept models indicated that changes in the mean ALT levels were significantly different over the time for MTX and MTX + INF/ETA groups (β [SE] =−0.190 [0.093], P= 0.040) but changes in the mean AST levels were nonsignificantly different over the time for such groups (β [SE] =−0.099 [0.064], P=0.120). CONCLUSION: Despite a higher incidence of elevated transaminases during the use of MTX + INF/ETA, the combination of INF/ETA with MTX reduced transaminase levels and returned ALT levels to normal concentrations. Dove Medical Press 2018-10-09 /pmc/articles/PMC6186305/ /pubmed/30349273 http://dx.doi.org/10.2147/TCRM.S172836 Text en © 2018 Akhlaghi et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Akhlaghi, Saeed
Sahebari, Maryam
Mahmoodi, Mahmoud
Yaseri, Mehdi
Mansournia, Mohammad Ali
Rafatpanah, Houshang
Zeraati, Hojjat
Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
title Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
title_full Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
title_fullStr Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
title_full_unstemmed Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
title_short Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
title_sort additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186305/
https://www.ncbi.nlm.nih.gov/pubmed/30349273
http://dx.doi.org/10.2147/TCRM.S172836
work_keys_str_mv AT akhlaghisaeed additionaleffectofetanerceptorinfliximabontheliverfunctiontestsofpatientswithrheumatoidarthritisacohortstudy
AT sahebarimaryam additionaleffectofetanerceptorinfliximabontheliverfunctiontestsofpatientswithrheumatoidarthritisacohortstudy
AT mahmoodimahmoud additionaleffectofetanerceptorinfliximabontheliverfunctiontestsofpatientswithrheumatoidarthritisacohortstudy
AT yaserimehdi additionaleffectofetanerceptorinfliximabontheliverfunctiontestsofpatientswithrheumatoidarthritisacohortstudy
AT mansourniamohammadali additionaleffectofetanerceptorinfliximabontheliverfunctiontestsofpatientswithrheumatoidarthritisacohortstudy
AT rafatpanahhoushang additionaleffectofetanerceptorinfliximabontheliverfunctiontestsofpatientswithrheumatoidarthritisacohortstudy
AT zeraatihojjat additionaleffectofetanerceptorinfliximabontheliverfunctiontestsofpatientswithrheumatoidarthritisacohortstudy